Compare · GILD vs IMA
GILD vs IMA
Side-by-side comparison of Gilead Sciences Inc. (GILD) and ImageneBio Inc. (IMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and IMA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $180.64B, about 2980.0x IMA ($60.6M).
- Over the past year, GILD is up 28.9% and IMA is down 61.0% - GILD leads by 90.0 points.
- GILD has been more active in the news (17 items in the past 4 weeks vs 15 for IMA).
- GILD has more recent analyst coverage (25 ratings vs 3 for IMA).
- Company
- Gilead Sciences Inc.
- ImageneBio Inc.
- Price
- $145.67-2.13%
- $5.33-5.16%
- Market cap
- $180.64B
- $60.6M
- 1M return
- +11.00%
- -6.49%
- 1Y return
- +28.93%
- -61.02%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 17
- 15
- Recent ratings
- 25
- 3
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- Director Welters Anthony exercised 18,000 shares at a strike of $61.06 and sold $2,675,220 worth of shares (18,000 units at $148.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form N-PX filed by Gilead Sciences Inc.
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
Latest IMA
- H.C. Wainwright initiated coverage on ImageneBio with a new price target
- Chief Executive Officer Yarema Kristin was granted 254,800 shares, increasing direct ownership by 107% to 493,705 units (SEC Form 4)
- Chief Financial Officer Grant-Huerta Yanina was granted 104,000 shares (SEC Form 4)
- ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form EFFECT filed by ImageneBio Inc.
- SEC Form EFFECT filed by ImageneBio Inc.
- SEC Form EFFECT filed by ImageneBio Inc.
- SEC Form S-8 filed by ImageneBio Inc.
- SEC Form S-3 filed by ImageneBio Inc.
- SEC Form POS AM filed by ImageneBio Inc.